RhumbLine Advisers’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

RhumbLine Advisers’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-9,000	Closed	-$5.9K	–	4324
2023 Q3	$5.9K	Hold	9,000	–	–	﹤0.01%	3951
2023 Q2	$3.6K	Buy	+9,000	New	+$6.36K	﹤0.01%	4135

RhumbLine Advisers's CYAD Position: Q4 2023 in Review

RhumbLine Advisers sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q4 2023, closing a stake of 9,000 shares — an estimated $5.9K sold.

RhumbLine Advisers first reported a position in CYAD in Q2 2023 and held it in 2 quarters. The position peaked at $5.9K in Q3 2023. 0 funds tracked by Wall St. Rank hold CYAD as of Q4 2023.

RhumbLine Advisers reported no remaining Celyad Oncology SA American Depositary Shares position as of Q4 2023 after selling out during the quarter.
RhumbLine Advisers sold 9,000 Celyad Oncology SA American Depositary Shares shares in Q4 2023, an estimated $5.9K.
RhumbLine Advisers first reported a position in Celyad Oncology SA American Depositary Shares in Q2 2023 and held it in 2 quarters.
RhumbLine Advisers's Celyad Oncology SA American Depositary Shares position peaked at $5.9K in Q3 2023.
0 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q4 2023.

Based on RhumbLine Advisers's 13F filing for Q4 2023, filed 8 Feb 2024.